On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Yorvipath1, intended for the treatment of chronic hypoparathyroidism in adults. The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S.

Yorvipath will be available as 168 µg/0.56 ml, 294 µg/0.98 ml and 420 µg/1.4 ml solutions for injection. The active substance of Yorvipath is palopegteriparatide, a transiently pegylated parathyroid hormone (ATC code: H05AA05) that in the body dissociates into parathyroid hormone and binds to and activates cell-surface parathyroid hormone receptors (PTH1R) similar to endogenous parathyroid hormone. 

The benefits of Yorvipath are the achievement of serum and urinary calcium levels in the normal range and independence from conventional therapy, as observed in a phase 3, double blind, placebo controlled study in adult patients with hypoparathyrodism. The most common side effects are injection site reactions, headache, and paraesthesia. Hypercalcaemia may occur, especially when starting Yorvipath or when increasing the dose, and patients should be monitored for signs and symptoms of hypercalcaemia.

The full indication is:

Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.
Yorvipath should be initiated and monitored by physicians experienced in the diagnosis and treatment of patients with hypoparathyroidism.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

1This product was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained

Key facts

Agency product number
International non-proprietary name (INN) or common name
  • Palopegteriparatide
Active substance
  • palopegteriparatide
Therapeutic area

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Date opinion adopted
Company name
Ascendis Pharma Bone Diseases A/S
Application type
Initial authorisation

How useful was this page?

Add your rating